Quitline Counsellors' Experiences With Vaping and Nicotine Replacement Therapy for Smoking Cessation in Australian Drug and Alcohol Services
Abstract
ABSTRACT Introduction In Australia, people undergoing inpatient treatment for alcohol and other drug (AOD) use disorders have a high prevalence of tobacco smoking. Smoking cessation support is routinely offered to clients within inpatient withdrawal settings, but continued support post‐discharge typically is not. The current study qualitatively explores attitudes and experiences of Quitline counsellors involved in a two‐armed trial for clients with provision of 12 weeks of nicotine vaping products (NVPs) or combination nicotine replacement therapy (cNRT). Methods Two focus groups of Quitline counsellors (six per group) explored how they felt about training received, their beliefs and attitudes about NVPs and cNRT for smoking cessation for AOD‐use population and their wider experience supporting AOD clients. Data were inductively coded. Results Six themes were identified: (i) Counsellor Readiness and Professional Adaptation to Emerging Cessation Tools; (ii) Addressing Complexity: Behavioural Support in Multi‐Substance Recovery Contexts; (iii) Client Preferences and Product Engagement in Cessation Support; (iv) Continuity of Care: Bridging Residential Treatment and Community Support; (v) Enablers of Quality Practice: Training, Resources and Organisational Support; and (vi) Service Integration and Boundary Management in Specialised Populations. Discussion and Conclusions The agility of Quitline services models their potential to partner with clinical research teams and AOD…
Read the paper
Related studies
- Tobacco and COPD: presenting the World Health Organization (WHO) Tobacco Knowledge Summary
- Comparative effects of e-cigarette smoking on periodontal status, salivary pH, and cotinine levels
- Association between exposure to environmental pollutants and increased oral health risks, a comprehensive review
- Influence of gestational window on offspring vascular health in rodents with in utero exposure to electronic cigarettes
- Natural products as kinase inhibitors in lung cancer: molecular mechanisms, therapeutic potential, and clinical trials
- Nicotine in electronic cigarettes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.